nejm.orgJuly 17, 2014
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Reported by nejm.org. Read the original →
What the story says
The headline indicates that the article discusses the use of Lanreotide in the treatment of metastatic enteropancreatic neuroendocrine tumors. Further details about the study or findings are not provided in the description.
Summarised by a model from nejm.org's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
LanreotideA · Human clinical
- Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.Human · RCT · n=169 · 2026
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Human · RCT · 2026
- Randomized controlled trial evaluating immunogenicity and safety of a porcine circovirus-free rotavirus vaccine in healthy Chinese infants.Human · RCT · 2026
What the headline doesn't tell you
- Lanreotide has 18 studies on file, 14 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.